Stay updated with breaking news from Jonathan Frampton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics,...
20 May 2021 Can gene editing technology help transition cell-based therapies to solid tumours? Here, Jonathan Frampton looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing Developing an allogeneic cell therapy is not without its challenges, including avoiding destruction by the patient’s immune system There have been two successful cell therapies that target the so called ‘liquid tumours’ (leukaemia and lymphoma). Both are chimeric antigen receptor (CAR) T cells -- Novartis’ Kymriah and...